Impaired immunomodulatory ability of bone marrow mesenchymal stem cells on CD4 + T cells in aplastic anemia

Results in Immunology

Volumn 2, Issue , 2012, Pages 142-147

  Li, Jianping ^a,b   Lu, Shihong ^a   Yang, Shaoguang ^a   Xing, Wen ^a   Feng, Jianming ^b   Li, Wenqian ^b   Zhao, Qinjun ^a   Wu, Hao ^a   Ge, Meili ^a   Ma, Fengxia ^a   Zhao, Hui ^c   Liu, Bin ^a   Zhang, Lei ^a   Zheng, Yizhou ^a   Han, Zhong Chao ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

^b Qinghai Provincial People's Hospital   (China)

^c TIANJIN UNIVERSITY OF COMMERCE   (China)

Author keywords

Aplastic anemia; Bone marrow mesenchymal stem cell; CD4 + T cells; Immunomodulation

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 4; PROSTAGLANDIN E2; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; APLASTIC ANEMIA; ARTICLE; BONE MARROW DEPRESSION; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL EXPANSION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; LYMPHOCYTE PROLIFERATION; MALE; MESENCHYMAL STEM CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE;

EID: 84867319476     PISSN: None     EISSN: 22112839     Source Type: Journal    
DOI: 10.1016/j.rinim.2012.07.002     Document Type: Article

References (30)

1. Li JP, Zheng CL, Han ZC Abnormal immunity and stem/progenitor cells in acquired aplastic anemia. Critical Reviews in Oncology/Hematology 2010, 75:79-93.
2. Young NS, Calado RT, Scheinberg P Current concepts in the pathophysiology and treatment of aplastic anemia. Blood 2006, 108:2509-2519.
3. Giannakoulas NC, Karakantza M, Theodorou GL, Pagoni M, Galanopoulos A, Kakagianni T, Kouraklis-Symeonidis A, Matsouka P, Maniatis A, Zoumbos NC Clinical relevance of balance between type 1 and type 2 immune responses of lymphocyte subpopulations in aplastic anaemia patients. British Journal of Haematology 2004, 124:97-105.
4. Solomou EE, Rezvani K, Mielke S, Malide D, Keyvanfar K, Visconte V, Kajigaya S, Barrett AJ, Young NS Deficient CD4+ CD25+ FOXP3+ T regulatory cells in acquired aplastic anemia. Blood 2007, 110:1603-1606.
5. Zoumbos NC, Gascon P, Djeu JY, Trost SR, Young NS Circulating activated suppressor T lymphocytes in aplastic anemia. New England Journal of Medicine 1985, 312:257-265.
6. de Latour RP, Visconte V, Takaku T, Wu C, Erie AJ, Sarcon AK, Desierto MJ, Scheinberg P, Keyvanfar K, Nunez O, Chen J, Young NS Th17 immune responses contribute to the pathophysiology of aplastic anemia. Blood 2010, 116:4175-4184.
7. Kordasti S, Marsh J, Al-Khan S, Jiang J, Smith A, Mohamedali A, Abellan PP, Veen C, Costantini B, Kulasekararaj AG, Benson-Quarm N, Seidl T, Mian SA, Farzaneh F, Mufti GJ Functional characterization of CD4+ T cells in aplastic anemia. Blood 2012, 119:2033-2043.
8. Sloand E, Kim S, Maciejewski JP, Tisdale J, Follmann D, Young NS Intracellular interferon-gamma in circulating and marrow T cells detected by flow cytometry and the response to immunosuppressive therapy in patients with aplastic anemia. Blood 2002, 100:1185-1191.
9. Verma A, Deb DK, Sassano A, Kambhampati S, Wickrema A, Uddin S, Mohindru M, Van Besien K, Platanias LC Cutting edge: activation of the p38 mitogen-activated protein kinase signaling pathway mediates cytokine-induced hemopoietic suppression in aplastic anemia. Journal of Immunology 2002, 168:5984-5988.
10. Li J, Zhao Q, Xing W, Feng J, Wu H, Li H, Ge M, Tian K, Li X, Zhou J, Liu B, Zhang L, Zheng Y, Han ZC Interleukin-27 enhances the production of tumour necrosis factor-alpha and interferon-gamma by bone marrow T lymphocytes in aplastic anaemia. British Journal of Haematology 2011, 153:764-772.
11. Manz CY, Nissen C, Wodnar-Filipowicz A Deficiency of CD34+ c-kit+ and CD34 + 38- hematopoietic precursors in aplastic anemia after immunosuppressive treatment. American Journal of Hematology 1996, 52:264-274.
12. Matsui WH, Brodsky RA, Smith BD, Borowitz MJ, Jones RJ Quantitative analysis of bone marrow CD34 cells in aplastic anemia and hypoplastic myelodysplastic syndromes. Leukemia 2006, 20:458-462.
13. Rizzo S, Scopes J, Elebute MO, Papadaki HA, Gordon-Smith EC, Gibson FM Stem cell defect in aplastic anemia: reduced long term culture-initiating cells (LTC-IC) in CD34+ cells isolated from aplastic anemia patient bone marrow. Hematology Journal 2002, 3:230-236.
14. Uccelli A, Moretta L, Pistoia V Mesenchymal stem cells in health and disease. Nature Reviews Immunology 2008, 8:726-736.
15. Le Blanc K, Samuelsson H, Gustafsson B, Remberger M, Sundberg B, Arvidson J, Ljungman P, Lonnies H, Nava S, Ringden O Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia 2007, 21:1733-1738.
16. Rasmusson I Immune modulation by mesenchymal stem cells. Experimental Cell Research 2006, 312:2169-2179.
17. Chen X, Armstrong MA, Li G Mesenchymal stem cells in immunoregulation. Immunology and Cell Biology 2006, 84:413-421.
18. Guo Z, Zheng C, Chen Z, Gu D, Du W, Ge J, Han Z, Yang R Fetal BM-derived mesenchymal stem cells promote the expansion of human Th17 cells, but inhibit the production of Th1 cells. European Journal of Immunology 2009, 39:2840-2849.
19. Tatara R, Ozaki K, Kikuchi Y, Hatanaka K, Oh I, Meguro A, Matsu H, Sato K, Ozawa K Mesenchymal stromal cells inhibit Th17 but not regulatory T-cell differentiation. Cytotherapy 2011, 13:686-694.
20. Bacigalupo A, Valle M, Podesta M, Pitto A, Zocchi E, De Flora A, Pozzi S, Luchetti S, Frassoni F, Van Lint MT, Piaggio G T-cell suppression mediated by mesenchymal stem cells is deficient in patients with severe aplastic anemia. Experimental Hematology 2005, 33:819-827.
21. Chao YH, Peng CT, Harn HJ, Chan CK, Wu KH Poor potential of proliferation and differentiation in bone marrow mesenchymal stem cells derived from children with severe aplastic anemia. Annals of Hematology 2010, 89:715-723.
22. Marsh JC, Ball SE, Cavenagh J, Darbyshire P, Dokal I, Gordon-Smith EC, Keidan J, Laurie A, Martin A, Mercieca J, Killick SB, Stewart R, Yin JA Guidelines for the diagnosis and management of aplastic anaemia. British Journal of Haematology 2009, 147:43-70.
23. Chen K, Wang D, Du WT, Han ZB, Ren H, Chi Y, Yang SG, Zhu D, Bayard F, Han ZC Human umbilical cord mesenchymal stem cells hUC-MSCs exert immunosuppressive activities through a PGE2-dependent mechanism. Clinical Immunology 2010, 135:448-458.
24. Jaganathan BG, Tisato V, Vulliamy T, Dokal I, Marsh J, Dazzi F, Bonnet D Effects of MSC co-injection on the reconstitution of aplastic anemia patient following hematopoietic stem cell transplantation. Leukemia 2010, 24:1791-1795.
25. Fang B, Li N, Song Y, Li J, Zhao RC, Ma Y Cotransplantation of haploidentical mesenchymal stem cells to enhance engraftment of hematopoietic stem cells and to reduce the risk of graft failure in two children with severe aplastic anemia. Pediatric Transplantation 2009, 13:499-502.
26. Wang H, Wang Z, Xue M, Liu J, Yan H, Guo Z Co-transfusion of haplo-identical hematopoietic and mesenchymal stromal cells to treat a patient with severe aplastic. Cytotherapy 2010, 12:563-565.
27. Gieseke F, Bohringer J, Bussolari R, Dominici M, Handgretinger R, Muller I Human multipotent mesenchymal stromal cells use galectin-1 to inhibit immune effector cells. Blood 2010, 116:3770-3779.
28. Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004, 103:4619-4621.
29. Sato K, Ozaki K, Oh I, Meguro A, Hatanaka K, Nagai T, Muroi K, Ozawa K Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 2007, 109:228-234.
30. Selmani Z, Naji A, Zidi I, Favier B, Gaiffe E, Obert L, Borg C, Saas P, Tiberghien P, Rouas-Freiss N, Carosella ED, Deschaseaux F Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+ CD25 high FOXP3+ regulatory T cells. Stem Cells 2008, 26:212-222.